Orchid Pharma to settle disputes with DBS Bank

The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes

Orchid Pharma's Alathur API facility successfully completes USFDA inspection

The Alathur facility specializes in the production of Cephalosporin antibiotics

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion

Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR

Orchid Pharma receives DCGI approval for combination of Cefepime and Enmetazobactam

DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable

Orchid Pharma's 'Exblifep' receives USFDA approval

Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA

Orchid Pharma's Exblifeb granted EMA approval

Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia

Orchid Pharma consolidated Q2 FY24 net profit up at Rs. 19.80 Cr

Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023

Orchid Pharma Q4 FY23 consolidated PAT up at Rs. 59.13 Cr

The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023